Psychedelic psilocybin-assisted therapy reduces depressive symptoms in adults with cancer and depression
Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression. Trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy when interviewed at the end of the trial. The findings are published by Wiley in two articles appearing online in CANCER, a peer-reviewed journal of the American Cancer Society.
By binding to a specific subtype of serotonin receptor in the brain, psilocybin can cause alterations to mood, ...













